RxDoctor Payments Data

Sarah Preslar

Family · Bakersfield, CANPI 1821411265

Payments from drug & device makers

$1,981in general payments, 2019–2025

Across 108 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$414
  • Amgen$365
  • Novo Nordisk$284
  • Lilly USA, LLC$179
  • Gilead$98
  • Dynavax Technologies Corporation$87
  • plus $553 from 14 others

What the payments were for

  • Food & beverage$1,981100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,981 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$320
Medicare patients
23
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$53,206
JardianceEmpagliflozin30$46,397
JanuviaSitagliptin Phosphate24$30,488
FarxigaDapagliflozin Propanediol18$24,786
RybelsusSemaglutide13$22,793
Xigduo XrDapaglifloz Propaned/Metformin22$20,157
Synjardy XrEmpagliflozin/Metformin Hcl15$19,607
TrulicityDulaglutide17$18,775
EliquisApixaban12$16,042
MounjaroTirzepatide12$12,214
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$11,658
Repatha SureclickEvolocumab17$10,286
Atorvastatin Calcium319$2,360
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,422
Albuterol Sulfate HfaAlbuterol Sulfate47$1,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$284$75,99871 claims
Lilly USA, LLCTrulicity, Mounjaro$179$30,98929 claims
MerckJanuvia$49$30,48824 claims
AstraZenecaFarxiga$57$24,78618 claims
PfizerEliquis$53$16,04212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →